Cytrellis Biosystems, Inc., a pioneer in novel medical aesthetic solutions, launched the updated ellacor® system, the first and only minimally invasive in-office solution to remove skin, treat wrinkles and rejuvenate skin. The launch of ellacor 2.0 marks a new era of growth and expansion for Cytrellis, fueled by the successful completion of a new financing round and the appointment of Dr. Denise Dajles as President and Chief Executive Officer.
ellacor 2.0 provides dermatologists and plastic surgeons with an unprecedented ability to improve age-related skin changes to help restore youthful beauty. The original ellacor system had a limited release in 2022. As 250 clinicians conducted more than 10,000 procedures, their feedback and insight were collected and studied to identify opportunities to improve the system. As a result, the newly launched ellacor 2.0 provides a simpler procedure technique, a 35% shorter procedure time and better patient outcomes, including significantly improved consistency of results, with 60% reduced time for patient healing and higher patient satisfaction.
“We are excited about the future as Cytrellis enters this new phase of growth,” said John McDonough, Executive Chair of the Board. “With ellacor 2.0 and Denise’s leadership, Cytrellis provides an efficacious non-surgical aesthetic treatment option that providers and patients seek. ellacor 2.0 will change the future of non-invasive aesthetic treatments.”
The financing round, which closed in December 2024, was led by existing investors ARCH Venture Partners, Sands Capital, and a large U.S. family office. The newly raised funds will support the growth and expansion of ellacor 2.0 into new accounts, markets and indications.
Dr. Dajles brings 20 years of leadership experience in the medical device and aesthetics industries, with a strong track record of driving innovation, operational excellence, and business growth. Before joining Cytrellis, she served as Chief Technical Officer at Sientra, where she led operations and innovation strategy, and held leadership roles at Establishment Labs. Dr. Dajles holds a Doctor of Engineering from George Washington University, as well as MS and BS degrees in Biomedical Engineering from Washington University.
“I am honored to join Cytrellis at this pivotal moment in the company’s growth,” said Dr. Dajles. “ellacor 2.0 is truly a game-changer. The updates to the system are the direct feedback we received from providers and patients, and showcase our commitment to providing patients with safe, effective, and minimally invasive solutions for skin removal and rejuvenation. I’m excited to join the talented Cytrellis team and lead our journey to redefine the aesthetics industry.”
